11-13-18 DRAFT 2019FL-0095/006

	OPIOID FATALITY REVIEW AMENDMENTS	
	2019 GENERAL SESSION	
	STATE OF UTAH	
LONG	TITLE	
Genera	al Description:	
	This bill creates a new position in the Office of the Medical Examiner and creates the	
	Opioid and Overdose Fatality Review Committee.	
Highli	ghted Provisions:	
	This bill:	
	• creates the position of an opioid fatality examiner within the Office of the Medical	
	Examiner;	
	• creates the Opioid and Overdose Fatality Review Committee within the Department	
	of Health; and	
	makes technical and conforming changes.	
Money	Appropriated in this Bill:	
	None	
Other	Special Clauses:	
	None	
U tah C	Code Sections Affected:	
ENAC'	TS:	
	26-4-30 , Utah Code Annotated 1953	
	26-7-10 , Utah Code Annotated 1953	
Be it er	nacted by the Legislature of the state of Utah:	
	Section 1. Section 26-4-30 is enacted to read:	
	26-4-30. Opioid fatality examiner.	
	(1) With funds appropriated by the Legislature for this purpose, the department shall	
orovide	e compensation, at a standard rate determined by the department, to an opioid fatality	
examin	<u>er.</u>	
	(2) The opioid fatality examiner shall:	
	(a) work with the medical examiner to compile data regarding opioid related deaths,	

2019FL-0095/006 11-13-18 DRAFT

33	including:
34	(i) toxicology information;
35	(ii) demographics; and
36	(iii) source of opioids;
37	(b) as relatives of the deceased are willing, gather information from relatives of the
38	deceased regarding the circumstances of the decedent's death;
39	(c) maintain a database of information described in Subsections (2)(a) and (b);
40	(d) coordinate no less than monthly with the suicide prevention coordinator described
41	in Subsection 62A-15-1101(2); and
42	(e) coordinate no less than quarterly with the Opioid Fatality Review Committee
43	described in Section 26-7-10.
44	Section 2. Section 26-7-10 is enacted to read:
45	26-7-10. Opioid and Overdose Fatality Review Committee.
46	(1) As used in this section:
47	(a) "Committee" means the Opioid and Overdose Fatality Review Committee created
48	in this section.
49	(b) "Opioid overdose death" means a death primarily caused by opioids or another
50	substance that closely resembles opioids.
51	(2) The department shall establish the Opioid and Overdose Fatality Review
52	Committee.
53	(3) The executive director of the department shall appoint a committee coordinator.
54	(4) The committee shall consist of:
55	(a) the attorney general, or the attorney general's designee;
56	(b) a state, county, or municipal law enforcement officer;
57	(c) the manager of the department's Violence Injury Program, or the manager's
58	designee;
59	(d) an emergency medical services provider;
60	(e) a representative from the Office of the Medical Examiner;
61	(f) a representative from the Division of Substance Abuse and Mental Health;
62	(g) a representative from the Office of Vital Records;
63	(h) a representative from the Office of Health Care Statistics;

11-13-18 DRAFT 2019FL-0095/006

64	(i) a representative from the Division of Occupational and Professional Licensing;
65	(j) a healthcare professional who specializes in the prevention, diagnosis, and treatment
66	of substance use disorder;
67	(k) a representative from a state or local jail or detention center;
68	(1) a representative from the Department of Corrections;
69	(m) a representative from Juvenile Justice Services; and
70	(n) any other individual whom the committee determines is necessary to fulfill the
71	committee's responsibilities under Subsection (7).
72	(5) The department shall give the committee access to all reports, records, and other
73	documents, including protected health information, that are relevant to the committee's
74	responsibilities under Subsection (7).
75	(6) The committee coordinator may request records that are relevant to the committee's
76	responsibilities under Subsection (7) through Title 63G, Chapter 2, Government Records
77	Access and Management Act, and by subpoena.
78	(7) The committee shall:
79	(a) conduct a multidisciplinary review of available information regarding a decedent of
80	an opioid overdose death, which review shall include:
81	(i) consideration of the decedent's points of contact with healthcare, social services,
82	criminal justice and other systems; and
83	(ii) identification of specific factors that put the individual at risk for opioid overdose;
84	(b) promote cooperation and coordination among government entities involved in
85	opioid misuse, abuse, or overdose prevention;
86	(c) develop an understanding of the causes and incidence of opioid overdose deaths in
87	the state;
88	(d) make recommendations for changes to law or policy that may prevent opioid
89	overdose deaths;
90	(e) inform public health and public safety entities of emerging trends in opioid
91	overdose deaths;
92	(f) monitor overdose trends on non-opioid overdose deaths; and
93	(g) review non-opioid overdose deaths in the manner described in Subsections (7)(a)
94	through (7)(e), when the committee determines that there are a substantial number of overdose

2019FL-0095/006 11-13-18 DRAFT

95	deaths in Utah caused by the use of a non-opioid.	
96	(8) A committee may interview a staff member, a provider, or any other person who	
97	may have knowledge or expertise that is relevant to the review of an opioid overdose death.	
98	(9) A majority vote of committee members present constitutes the action of the	
99	committee.	
100	(10) Each committee member and each individual granted access to a committee	
101	proceeding shall sign a confidentiality agreement, created by the department, indicating that the	
102	individual agrees to:	
103	(a) keep confidential all information relating to the review of an opioid overdose death;	
104	<u>and</u>	
105	(b) not release any information relating to the review of an opioid overdose death,	
106	unless required or permitted by law to release the information.	
107	(11) The committee shall meet at least eight times each year.	
108	(12) Committee meetings are closed to the public.	
109	(13) The committee shall record minutes of committee meetings.	

- 4 -